{
    "clinical_study": {
        "@rank": "129638", 
        "brief_summary": {
            "textblock": "Patients are exposed to infectious agents regularly, regardless of their immunologic status.\n       Traditionally clinicians have decided to institute prophylaxis based on epidemiologic\n      factors, skin test (i.e. PPD), or immunologic parameters.  A quantitative and specific\n      method that is non-invasive, such as quantitative PCR, would be desirable to more precisely\n      define those who would benefit from prophylaxis.  Similarly, when patients develop disease\n      and are being treated, quantitative, non-invasive techniques are needed to assess response\n      to therapy.  This project is designed to develop and test quantitative tests using blood,\n      urine, or sputum samples."
        }, 
        "brief_title": "Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy", 
        "completion_date": "October 2000", 
        "condition": [
            "Communicable Diseases", 
            "Opportunistic Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Communicable Diseases", 
                "Infection", 
                "Opportunistic Infections"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients are exposed to infectious agents regularly, regardless of their immunologic status.\n       Traditionally clinicians have decided to institute prophylaxis based on epidemiologic\n      factors, skin test (i.e. PPD), or immunologic parameters.  A quantitative and specific\n      method that is non-invasive, such as quantitative PCR, would be desirable to more precisely\n      define those who would benefit from prophylaxis.  Similarly, when patients develop disease\n      and are being treated, quantitative, non-invasive techniques are needed to assess response\n      to therapy.  This project is designed to develop and test quantitative tests using blood,\n      urine, or sputum samples."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Patients older than 18 years of age.\n\n        Ability to give informed consent.\n\n        No medical contraindication to phlebotomy.\n\n        Epidemiologically at risk for tuberculosis or for an opportunistic infection.\n\n        Patients who can identify a responsible health care provider as someone willing to provide\n        clinical information and to receive medically important information."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "300", 
        "firstreceived_date": "November 3, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001477", 
            "org_study_id": "950176", 
            "secondary_id": "95-I-0176"
        }, 
        "keyword": [
            "Communicable Infection", 
            "Monitoring", 
            "Non-Invasive Tests", 
            "Opportunistic Infection"
        ], 
        "lastchanged_date": "March 3, 2008", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "National Institute of Allergy and Infectious Diseases (NIAID)"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "reference": [
            {
                "PMID": "7714198", 
                "citation": "Drouet E, Colimon R, Michelson S, Fourcade N, Niveleau A, Ducerf C, Boibieux A, Chevallier M, Denoyel G. Monitoring levels of human cytomegalovirus DNA in blood after liver transplantation. J Clin Microbiol. 1995 Feb;33(2):389-94."
            }, 
            {
                "PMID": "8077384", 
                "citation": "Patel R, Smith TF, Espy M, Wiesner RH, Krom RA, Portela D, Paya CV. Detection of cytomegalovirus DNA in sera of liver transplant recipients. J Clin Microbiol. 1994 Jun;32(6):1431-4."
            }, 
            {
                "PMID": "1328287", 
                "citation": "Spector SA, Merrill R, Wolf D, Dankner WM. Detection of human cytomegalovirus in plasma of AIDS patients during acute visceral disease by DNA amplification. J Clin Microbiol. 1992 Sep;30(9):2359-65."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001477"
        }, 
        "source": "National Institutes of Health Clinical Center (CC)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "August 1995", 
        "study_design": "N/A", 
        "study_type": "Observational", 
        "verification_date": "February 2000"
    }, 
    "geocoordinates": {
        "National Institute of Allergy and Infectious Diseases (NIAID)": "38.985 -77.095"
    }
}